FAP and cancer: Several clinical studies have highlighted the usefulness of gallium-labeled FAP inhibitor in imaging cancer cells due to the high-affinity complex with FAP (Figure 4), demonstrating 68Ga-FAPI PET/CT to be highly feasible [76,77], particularly because of the low physiological uptake in the human body, with high target-to-background ratio [78].